Bristol-Myers Squibb Company (NYSE: BMY) announced their new research results at the 18th Conference of the Asia-Pacific Association for the Study of the Liver (APASL) in Seoul, Korea. New BARACLUDEｮ (entecavir) data presented today demonstrated a continued low incidence of resistance in nucleoside-na・e patients through five years of treatment. In the nucleoside-na・e chronic hepatitis B patients analyzed, no additional patient developed resistance in the fifth year (n=108). Through five years of treatment, the cumulative probability of developing mutations in the virus that confer resistance to BARACLUDE (also called genotypic resistance) was 1.2 percent.
In lamivudine-refractory patients who received BARACLUDE after treatment with lamivudine failed, the cumulative probability of genotypic BARACLUDE resistance was 51 percent through the fifth year. This finding is consistent with prior observations that the pre-existence of lamivudine-resistant mutations results in an increase in the rate of BARACLUDE resistance.
Many chronic hepatitis B patients require long-term treatment. Unfortunately, the initial benefits of therapy can be lost after the development of resistance. These five-year BARACLUDE data that demonstrate long-term minimal resistance at 1.2 percent in nucleoside-naive patients can be of great importance for patients,・said Professor Ching-Lung Lai, Chief, Division of Gastroenterology and Hepatology, University of Hong Kong.
Drug resistance occurs when the hepatitis B virus (HBV) mutates, thereby avoiding the effects of the medication. This can decrease the efficacy of the current medication and may compromise future treatment options. To date, studies have shown that multiple mutations are required to develop BARACLUDEｮ (entecavir) resistance.
these long-term BARACLUDE data continue to support the observations seen in the first years of treatment and are reflective of BARACLUDE痴 high genetic barrier to resistance,・said Helena Brett-Smith, M.D., Group Director of Clinical Research at Bristol-Myers Squibb. 溺ore importantly, we believe the data support BARACLUDE as an important initial treatment choice for chronic hepatitis B, which is a disease that results in a large global health burden.